Delcath Systems, Inc. today announced it has received its first commercial order for the Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (BATS:IEO), which is one of Europe's premier cancer treatment and research centers. Delcath announced in November 2011 an initial launch and training agreement with IEO.
This milestone order of Delcath's CHEMOSAT system marks the company's transition from a research and development company to a commercial enterprise. Moving forward with its European launch plans, Delcath also recently announced its fifth training center in the European Union, and the company expects to announce additional center agreements over the course of 2012. The hiring and training of Delcath's direct sales force is accelerating, and the staffing of the company's contract medical science liaison team is also going forward. Delcath is additionally evaluating potential third-party distribution partners to cover each of its Southern Europe target markets.
Delcath's present goal is to establish CHEMOSAT as a new treatment option in Europe for patients with cancers in the liver. CHEMOSAT is a proprietary product utilizing chemosaturation technology, which is a minimally invasive, repeatable procedure administering high-dose chemotherapy directly to the liver while minimizing systemic exposure of the drug. CHEMOSAT was given CE Mark approval in April of 2011.
Delcath Systems is a specialty pharmaceutical and medical device company with its focus on oncology. The company's proprietary chemosaturation system is designed to administer high-dose chemotherapy and other therapeutic agents to diseased organs or body regions while simultaneously controlling the systemic exposure of those agents. Delcath's initial focus is treating primary and metastatic liver cancers.
For more information, visit the company's Web site at www.delcath.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html